HK1204913A1 - Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent - Google Patents

Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent Download PDF

Info

Publication number
HK1204913A1
HK1204913A1 HK15103663.3A HK15103663A HK1204913A1 HK 1204913 A1 HK1204913 A1 HK 1204913A1 HK 15103663 A HK15103663 A HK 15103663A HK 1204913 A1 HK1204913 A1 HK 1204913A1
Authority
HK
Hong Kong
Prior art keywords
halofenate
agent
gout
patients
antiinflammatory agent
Prior art date
Application number
HK15103663.3A
Other languages
English (en)
Chinese (zh)
Inventor
Gopal Chandra SAHA
Brian Edward LAVAN
Brian K. ROBERTS
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Diatex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc., Diatex, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of HK1204913A1 publication Critical patent/HK1204913A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103663.3A 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent HK1204913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
US201261624186P 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
HK1204913A1 true HK1204913A1 (en) 2015-12-11

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103663.3A HK1204913A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent

Country Status (15)

Country Link
US (1) US20130274331A1 (https=)
EP (1) EP2836209A4 (https=)
JP (1) JP2015512948A (https=)
KR (1) KR20150002799A (https=)
CN (1) CN104602686A (https=)
AU (1) AU2013245675B2 (https=)
CA (1) CA2870014A1 (https=)
CL (1) CL2014002728A1 (https=)
EA (1) EA028495B1 (https=)
HK (1) HK1204913A1 (https=)
IL (1) IL235154A0 (https=)
MX (1) MX2014012376A (https=)
PH (1) PH12014502282A1 (https=)
SG (1) SG11201406495UA (https=)
WO (1) WO2013155478A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
CA2909370A1 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP7850976B2 (ja) * 2021-08-31 2026-04-24 国立大学法人広島大学 体液サンプリング容器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
UA109638C2 (uk) * 2008-03-13 2015-09-25 Сполуки та спосіб зниження рівня сечової кислоти
CN102123595A (zh) * 2008-03-14 2011-07-13 因特里赫伯有限责任公司 抑制龋齿形成的甘草棒棒糖
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
ES2698396T3 (es) * 2011-11-04 2019-02-04 Cymabay Therapeutics Inc Métodos para tratar los brotes de gota
CN109908124A (zh) * 2011-11-04 2019-06-21 西玛贝医药公司 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
CN104066323A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 用于治疗患者亚群中痛风的方法

Also Published As

Publication number Publication date
US20130274331A1 (en) 2013-10-17
CL2014002728A1 (es) 2015-06-19
EP2836209A4 (en) 2015-11-25
MX2014012376A (es) 2015-06-05
PH12014502282A1 (en) 2014-12-15
WO2013155478A1 (en) 2013-10-17
AU2013245675B2 (en) 2017-02-09
EA201491870A1 (ru) 2015-03-31
KR20150002799A (ko) 2015-01-07
CN104602686A (zh) 2015-05-06
SG11201406495UA (en) 2014-11-27
IL235154A0 (en) 2014-12-31
AU2013245675A1 (en) 2014-10-30
CA2870014A1 (en) 2013-10-17
EA028495B1 (ru) 2017-11-30
EP2836209A1 (en) 2015-02-18
JP2015512948A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
JP2012184234A5 (https=)
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
BR112013022332A2 (pt) métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica
NZ597059A (en) Inhibitors of influenza viruses replication
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
EA201100778A1 (ru) Гетероциклические замещенные соединения в качестве ингибиторов hif
MX2014005400A (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
HK1204913A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
EA201490928A1 (ru) Способы лечения острых приступов подагры
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
CY1124383T1 (el) Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας
CA2794655A1 (en) Method for treating schizophrenia and related diseases
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
JP2014532758A5 (https=)
WO2013003899A8 (en) Methods of treating or preventing rheumatic disease
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
NZ624714A (en) Methods for treating gout in patient subpopulations
WO2009045054A3 (en) A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof
EA201591218A1 (ru) Способы и композиции для введения оксибутинина